Vertex Pharmaceuticals (VRTX) Equity Average (2010 - 2026)
Vertex Pharmaceuticals' quarterly Equity Average came in at $19.0 billion in Q1 2026, up 15.56% year-on-year from $16.5 billion in Q1 2025, and up 5.68% quarter-over-quarter from $18.0 billion in Q4 2025.
Vertex Pharmaceuticals has reported Equity Average for 17 years, with the latest figure at $19.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 15.56% year-over-year to $19.0 billion; the trailing twelve-month figure through Mar 2026 stood at $19.0 billion (up 15.56% YoY), and the FY2025 full-year result was $17.5 billion, up 3.19% from the prior year.
- Equity Average for Q1 2026 stood at $19.0 billion, up from $18.0 billion in the prior quarter.
- The five-year high for Equity Average was $19.0 billion in Q1 2026, with the low at $10.5 billion in Q1 2022.
- Average Equity Average over 5 years is $15.5 billion, with a median of $16.0 billion recorded in 2024.
- Year-over-year, Equity Average soared 37.25% in 2022 and fell 8.92% in 2025.
- Tracing VRTX's Equity Average over 5 years: stood at $13.5 billion in 2022, then increased by 26.54% to $17.0 billion in 2023, then dropped by 6.02% to $16.0 billion in 2024, then increased by 12.31% to $18.0 billion in 2025, then increased by 5.68% to $19.0 billion in 2026.
- The last three Equity Average figures came in at $19.0 billion (Q1 2026), $18.0 billion (Q4 2025), and $17.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.01 Bn |
| Dec 31, 2025 | 17.99 Bn |
| Sep 30, 2025 | 17.25 Bn |
| Jun 30, 2025 | 16.84 Bn |
| Mar 31, 2025 | 16.45 Bn |
| Dec 31, 2024 | 16.02 Bn |
| Sep 30, 2024 | 15.20 Bn |
| Jun 30, 2024 | 16.66 Bn |
| Mar 31, 2024 | 18.06 Bn |
| Dec 31, 2023 | 17.05 Bn |
| Sep 30, 2023 | 15.99 Bn |
| Jun 30, 2023 | 14.95 Bn |
| Mar 31, 2023 | 14.17 Bn |
| Dec 31, 2022 | 13.47 Bn |
| Sep 30, 2022 | 12.48 Bn |
| Jun 30, 2022 | 11.42 Bn |
| Mar 31, 2022 | 10.50 Bn |
| Dec 31, 2021 | 9.82 Bn |
| Sep 30, 2021 | 9.36 Bn |
| Jun 30, 2021 | 9.09 Bn |
| Mar 31, 2021 | 8.83 Bn |
| Dec 31, 2020 | 8.41 Bn |
| Sep 30, 2020 | 7.83 Bn |
| Jun 30, 2020 | 6.99 Bn |
| Mar 31, 2020 | 6.27 Bn |
| Dec 31, 2019 | 5.67 Bn |
| Sep 30, 2019 | 5.16 Bn |
| Jun 30, 2019 | 4.90 Bn |
| Mar 31, 2019 | 4.58 Bn |
| Dec 31, 2018 | 3.68 Bn |
| Sep 30, 2018 | 2.82 Bn |
| Jun 30, 2018 | 2.57 Bn |
| Mar 31, 2018 | 2.24 Bn |
| Dec 31, 2017 | 1.92 Bn |
| Sep 30, 2017 | 1.84 Bn |
| Jun 30, 2017 | 1.78 Bn |
| Mar 31, 2017 | 1.51 Bn |
| Dec 31, 2016 | 1.27 Bn |
| Sep 30, 2016 | 1.19 Bn |
| Jun 30, 2016 | 1.14 Bn |
| Mar 31, 2016 | 1.10 Bn |
| Dec 31, 2015 | 1.09 Bn |
| Sep 30, 2015 | 1.06 Bn |
| Jun 30, 2015 | 1.02 Bn |
| Mar 31, 2015 | 1.05 Bn |
| Dec 31, 2014 | 1.13 Bn |
| Sep 30, 2014 | 1.16 Bn |
| Jun 30, 2014 | 1.20 Bn |
| Mar 31, 2014 | 1.29 Bn |
| Dec 31, 2013 | 1.40 Bn |
| Sep 30, 2013 | 1.48 Bn |
| Jun 30, 2013 | 1.22 Bn |
| Mar 31, 2013 | 1.07 Bn |
| Dec 31, 2012 | 1.21 Bn |
| Sep 30, 2012 | 1.22 Bn |
| Jun 30, 2012 | 1.14 Bn |
| Mar 31, 2012 | 998.28 Mn |
| Dec 31, 2011 | 811.31 Mn |
| Mar 31, 2011 | 447.82 Mn |
| Dec 31, 2010 | 577.03 Mn |
| Sep 30, 2010 | 738.62 Mn |
| Jun 30, 2010 | 908.87 Mn |
| Mar 31, 2010 | 1.04 Bn |